Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  215.20
+3.46 (1.63%)
AAPL  254.23
+1.41 (0.56%)
AMD  196.31
-0.27 (-0.14%)
BAC  47.28
+0.22 (0.47%)
GOOG  309.41
+4.99 (1.64%)
META  622.66
-4.79 (-0.76%)
MSFT  399.41
-0.54 (-0.14%)
NVDA  181.93
-1.29 (-0.70%)
ORCL  154.69
-1.28 (-0.82%)
TSLA  399.27
+3.71 (0.94%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.